CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the abstract “Demonstration of a Proof-of-Concept Device for Delivering Bioengineered Neural Stem Cell Trails to the Spinal Cord” has been accepted for presentation at the 2016 Tissue Engineering & Regenerative Medicine International Society (TERMIS) Americas Annual Conference and Exhibition, to be held December 11-14, 2016 in San Diego, CA. Artem Kutikov, Ph.D., Research Scientist, will be giving the poster presentation. The abstract is co-authored Dr. Kutikov, Richard Layer, Ph.D., Simon Moore, Ph.D., Alex Aimetti, Ph.D., Christoph Hofstetter, M.D., Ph.D., James Guest, M.D., Ph.D., and Thomas Ulich, M.D.
Mark Perrin, InVivo’s CEO and Chairman, said, “This presentation describes the design and validation of the TrailMaker™, a proof-of-concept device capable of producing longitudinal cellular transplants in the spinal cord of animal models. The current version of the TrailMaker will only be used preclinically, but this prototype device will inform and enable the design of the next generation device that we hope to study in the clinic in order to help those with chronic spinal cord injuries.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold™ received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect," “designed to,” “potentially,” and similar expressions, and include statements regarding the company’s ability to translate the TrailMaker proof-of-concept into the clinic. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.
